BMS combined Opdivo with Fotovda in the treatment of kidney cancer and AVEO...

CompilationFan Dongdong

A few days ago, AVEO Oncology announced that it has signed a clinical trial cooperation and supply agreement with Bristol Myers Squibb to study the combination of Fotivda (tivozanib) and Bristol Myers Squibb's PD-1 tumor drug Opdivo (nivolumab) for the treatment of advanced immunotherapy.

AVEO and Bristol-Myers Squibb plan to open an open-label controlled phase III clinical trial of TiNivo-2 in the United States, Europe and Latin America, and it is expected that 326 patients will be enrolled.

In the previous phase II study, the combination of Fotivda and Bristol-Myers Squibb Opdivo showed a synergistic effect.

AVEO targets the anti-cancer drug Fotivda, which is a next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) that is taken orally once a day.

The approval of Fotivda is based on the results of the pivotal phase III clinical study TIVO-3.

The results of the TIVO-3 trial showed that the median progression-free survival (PFS) of patients treated with Fotivda was 5.

Reference source:

1.